The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
EGFR signal transactivation in cancer cells
Abstract
The EGFR (epidermal growth factor receptor) plays a key role in the regulation of essential normal cellular processes and in the pathophysiology of hyperproliferative diseases such as cancer. Recent investigations have demonstrated that GPCRs (G-protein-coupled receptors) are able to utilize the EGFR as a downstream signalling partner in the generation of mitogenic signals. This cross-talk mechanism combines the broad diversity of GPCRs with the signalling capacities of the EGFR and has emerged as a general concept in a multitude of cell types. The molecular mechanisms of EGFR signal transactivation involve processing of transmembrane growth factor precursors by metalloproteases which have been recently identified as members of the ADAM (adisintegrin and metalloprotease) family of zinc-dependent proteases. Subsequently, the EGFR transmits signals to prominent downstream pathways, such as mitogen-activated protein kinases, the phosphoinositide 3-kinase/Akt pathway and modulation of ion channels. Analysis of GPCR-induced EGFR activation in more than 60 human carcinoma cell lines derived from different tissues has demonstrated the broad relevance of this signalling mechanism in cancer. Moreover, EGFR signal transactivation was linked to diverse biological processes in human cancer cells, such as cell proliferation, migration and anti-apoptosis. Together with investigations revealing the importance of this GPCR–EGFR cross-talk mechanism in cardiac hypertrophy, Helicobacter pylori-induced pathophysiological processes and cystic fibrosis, these findings support an important role for GPCR ligand-dependent EGFR signal transactivation in diverse pathophysiological disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adomeit, A., Graneß, A., Groß, S., Seedorf, K., Wetzker, R., & Liebmann, C. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.8.5289 · Cited by 106
Cited by
Cell-signalling dynamics in time and space
Kholodenko, B. N. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1838 · Cited by 1,347
EDWARDS, D., HANDSLEY, M., & PENNINGTON, C. (2008) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2008.08.001 · Cited by 1,161
ADAMs: key components in EGFR signalling and development
Blobel, C. P. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1548 · Cited by 1,090
The Epidermal Growth Factor Receptor Pathway: A Model for Targeted Therapy
Scaltriti, M., & Baselga, J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1554 · Cited by 913
G protein-coupled receptors: novel targets for drug discovery in cancer
Lappano, R., & Maggiolini, M. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3320 · Cited by 717
Basic Principles and Emerging Concepts in the Redox Control of Transcription Factors
Brigelius-Flohé, R., & Flohé, L. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3534 · Cited by 576
A comprehensive summary of LL-37, the factotum human cathelicidin peptide
Vandamme, D., Landuyt, B., Luyten, W., & Schoofs, L. (2012) · Cellular Immunology · doi:10.1016/j.cellimm.2012.11.009 · Cited by 567
The epidermal growth factor receptor ligands at a glance
Schneider, M. R., & Wolf, E. (2009) · Journal of Cellular Physiology · doi:10.1002/jcp.21635 · Cited by 447
The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer
Hsu, J. L., & Hung, M.-C. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9649-6 · Cited by 445
Autocrine, paracrine and juxtacrine signaling by EGFR ligands
Singh, A. B., & Harris, R. C. (2005) · Cellular Signalling · doi:10.1016/j.cellsig.2005.03.026 · Cited by 400
Yan, F., Cao, H., Cover, T. L., Washington, M. K., Shi, Y., Liu, L., Chaturvedi, R., Peek, R. M., Wilson, K. T., & Polk, D. B. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44031 · Cited by 375
Role of the Epidermal Growth Factor Network in Ovarian Follicles
Conti, M., Hsieh, M., Park, J.-Y., & Su, Y.-Q. (2006) · Molecular Endocrinology · doi:10.1210/me.2005-0185 · Cited by 371
ADAMs as mediators of EGF receptor transactivation by G protein-coupled receptors
Ohtsu, H., Dempsey, P. J., & Eguchi, S. (2006) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00620.2005 · Cited by 338
Horiuchi, K., Le Gall, S., Schulte, M., Yamaguchi, T., Reiss, K., Murphy, G., Toyama, Y., Hartmann, D., Saftig, P., & Blobel, C. P. (2007) · Molecular Biology of the Cell · doi:10.1091/mbc.e06-01-0014 · Cited by 310
Mechanism of short-term ERK activation by electromagnetic fields at mobile phone frequencies
Friedman, J., Kraus, S., Hauptman, Y., Schiff, Y., & Seger, R. (2007) · Biochemical Journal · doi:10.1042/bj20061653 · Cited by 288
RetractedHart, S., Fischer, O. M., & Ullrich, A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3720 · Cited by 288
Self-citationNeurotrophin signaling: many exciting surprises!
Arévalo, J. C., & Wu, S. H. (2006) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-006-6010-1 · Cited by 281
The complexity of targeting EGFR signalling in cancer: From expression to turnover
Sebastian, S., Settleman, J., Reshkin, S. J., Azzariti, A., Bellizzi, A., & Paradiso, A. (2006) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2006.06.001 · Cited by 260
Rajagopal, R., Chen, Z.-Y., Lee, F. S., & Chao, M. V. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.0010-04.2004 · Cited by 257
Current targeted therapies in the treatment of advanced colorectal cancer: a review
Moriarity, A., O’Sullivan, J., Kennedy, J., Mehigan, B., & McCormick, P. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834016646734 · Cited by 87
Gao, M., Zhan, Y.-Q., Yu, M., Ge, C.-H., Li, C.-Y., Zhang, J.-H., Wang, X.-H., Ge, Z.-Q., & Yang, X.-M. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2014.04.013 · Cited by 52
Joseph, B. B., Edeen, P. T., Meadows, S., Binti, S., & Fay, D. S. (2022) · PLOS Genetics · doi:10.1371/journal.pgen.1010249 · Cited by 13
Metadata
- Authors
- Fischer, O. M., Hart, S., Gschwind, A., & Ullrich, A.
- Venue
- Biochemical Society Transactions
- Publisher
- Portland Press Ltd.
- Published
- 2003-12-01
- Volume
- 31
- Issue
- 6
- Pages
- 1203-1208
- ISSN
- 0300-5127 (ISSN-L)
- 1470-8752
- OpenAlex
- W1986137370
- Cited by
- 411
- References
- 1
- FWCI
- 12.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.